East Bay gene editing company snags Gilead deal worth up to $3.2 billion

Sangamo Therapeutics Inc.'s gene-editing technology is playing second fiddle to CRISPR no longer. The Richmond-based company (NASDAQ: SGMO) Thursday disclosed a deal with Kite, a subsidiary of Foster City-based Gilead Sciences Inc. (NASDAQ: GILD), to develop next-generation cell therapies in cancer. It will receive $150 million upfront but could receive $3 billion more over the course of the c ollaboration by hitting a series of milestones. The deal is a huge win for Sangamo, whose zinc finger nucleases…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news